ENDV (Endonovo Therapeutics) Shiller PE Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Endonovo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Endonovo Therapeutics  (OTCPK:ENDV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Endonovo Therapeutics Shiller PE Ratio Related Terms


Endonovo Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Shiller PE Ratio Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENDV vs RGBP, SIGY, CNBX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Shiller PE Ratio falls into.



Endonovo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Endonovo Therapeutics's E10 for the quarter that ended in Jun. 2025 is calculated as:

For example, Endonovo Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=-0/322.5610*322.5610
=0.000

Current CPI (Jun. 2025) = 322.5610.

Endonovo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201509 -10.000 237.945 -13.556
201512 -50.000 236.525 -68.188
201603 -10.000 238.132 -13.545
201606 -10.000 241.018 -13.383
201609 -20.000 241.428 -26.721
201612 -10.000 241.432 -13.360
201703 -50.000 243.801 -66.153
201706 10.000 244.955 13.168
201709 -30.000 246.819 -39.206
201712 20.000 246.524 26.169
201803 -1.890 249.554 -2.443
201806 -3.595 251.989 -4.602
201809 -20.000 252.439 -25.556
201812 2.240 251.233 2.876
201903 -4.990 254.202 -6.332
201906 -13.570 256.143 -17.089
201909 -1.810 256.759 -2.274
201912 -5.830 256.974 -7.318
202003 -0.140 258.115 -0.175
202006 -0.170 257.797 -0.213
202009 -0.070 260.280 -0.087
202012 -0.083 260.474 -0.103
202103 -0.060 264.877 -0.073
202106 -0.020 271.696 -0.024
202109 -0.020 274.310 -0.024
202112 0.050 278.802 0.058
202203 -0.030 287.504 -0.034
202206 -0.020 296.311 -0.022
202209 -0.004 296.808 -0.004
202212 -0.080 296.797 -0.087
202303 0.000 301.836 0.000
202306 0.007 305.109 0.007
202309 -0.002 307.789 -0.002
202312 -0.005 306.746 -0.005
202403 0.000 312.332 0.000
202406 -0.002 314.175 -0.002
202409 -0.002 315.301 -0.002
202412 -0.001 315.605 -0.001
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.